Fatal Hepatitis Mediated by Tumor Necrosis Factor TNFα Requires Caspase-8 and Involves the BH3-Only Proteins Bid and Bim

Thomas Kaufmann,1,7 Philipp J. Jost,1,6 Marc Pellegrini,2,6 Hamsa Puthalakath,1,8 Raffi Gugasyan,1,9 Steve Gerondakis,1,9 Erika Cretney,3,10 Mark J. Smyth,3 John Silke,4 Razq Hakem,2 Philippe Bouillet,1 Tak W. Mak,2 Vishva M. Dixit,6 and Andreas Strasser1,*

1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia
2Ontario Cancer Institute, University of Toronto, Toronto, Ontario M5G 2C1, Canada
3The Peter MacCallum Cancer Centre, Melbourne, VIC 3002, Australia
4LaTrobe University, Bundoora, VIC 3086, Australia
5Genentech, Inc., South San Francisco, CA 94080-4990, USA
6These authors contributed equally to this work
7Present address: Institute of Pharmacology, University of Bern, 3010 Bern, Switzerland
8Present address: LaTrobe University, Bundoora, VIC 3086, Australia
9Present address: Macfarlane Burnet Institute for Medical Research and Public Health, Prahran, VIC 3004, Australia
10Present address: The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia
*Correspondence: strasser@wehi.edu.au
DOI 10.1016/j.immuni.2008.10.017

SUMMARY

Apoptotic death of hepatocytes, a contributor to many chronic and acute liver diseases, can be a consequence of overactivation of the immune system and is often mediated by TNFα. Injection with lipopolysaccharide (LPS) plus the transcriptional inhibitor D-(+)-galactosamine (GalN) or mitogenic T cell activation causes fatal hepatocyte apoptosis in mice, which is mediated by TNFα, but the effector mechanisms remain unclear. Our analysis of gene-targeted mice showed that caspase-8 is essential for hepatocyte killing in both settings. Loss of Bid, the proapoptotic BH3-only protein activated by caspase-8 and essential for Fas ligand-induced hepatocyte killing, resulted only in a minor reduction of liver damage. However, combined loss of Bid and another BH3-only protein, Bim, activated by c-Jun N-terminal kinase (JNK), protected mice from LPS+GalN-induced hepatitis. These observations identify caspase-8 and the BH3-only proteins Bid and Bim as potential therapeutic targets for treatment of inflammatory liver diseases.

INTRODUCTION

Abnormal apoptotic death of hepatocytes is thought to be a cause or contributing factor in many chronic as well as acute liver diseases (reviewed in Bradham et al., 1998; Ding and Yin, 2004). Tumor necrosis factor (TNFα), FasL, and related members of the TNF cytokine family have been implicated in hepatocyte killing but the signaling pathways contributing to development and progression of these diseases are presently unclear. The molecular basis of hepatocyte destruction in hepatitis can be studied with mouse models. For example, injection of low doses of bacterial lipopolysaccharide (LPS) in the presence of the liver-specific transcriptional inhibitor D-(+)-galactosamine (GalN) or treatment with the T cell mitogen concanavalin A (ConA) causes fatal hepatocyte destruction. In both settings, TNFα is essential for hepatocyte killing and animal mortality (Pfeffer et al., 1993; Rothe et al., 1993; independently confirmed by us for both treatments, see Figure S1 available online). Secreted TNFα appears to be critical in LPS+GalN-injected mice, whereas both secreted and membrane-bound TNFα contribute to hepatocyte destruction in ConA-injected animals (Grivennikov et al., 2005; Nowak et al., 2000; Pfeffer et al., 1993; Rothe et al., 1993). The mechanisms by which TNFα kills hepatocytes are still unclear. TNF-R1 has an intracellular “death domain” and therefore belongs to the “death receptor” subgroup within the TNF-R family, which also includes Fas (APO-1 or CD95), DR3, and the TRAIL receptors DR4 and DR5 (Ashkenazi and Dixit, 1998). Genetic and biochemical studies, using fibroblasts from gene-targeted mice, have shown that TNF-R1 triggers apoptosis by binding the adaptor proteins TRADD and FADD, which facilitate recruitment and activation of the aspartate-specific cysteine protease caspase-8 (Ashkenazi and Dixit, 1998). Signaling through the c-Jun N-terminal kinase (JNK) has also been implicated in TNFα-induced apoptosis signaling (Baud et al., 1999; Kamata et al., 2005; Wang et al., 2006), but the death effectors acting downstream of JNK in this process have not yet been identified. Caspase-8 can proteolytically activate the proapoptotic BH3-only Bcl-2 family member BID (Li et al., 1998; Luo et al., 1998), which triggers apoptosis by activating Bax and Bak (members of the second proapoptotic subgroup within the Bcl-2 family), either directly or indirectly by binding to prosurvival Bcl-2 family members (e.g., Bcl-xL and Mcl-1) (Zha et al., 2000). Experiments with gene-targeted mice have shown that caspase-8 and Bid are both essential for Fas-induced apoptosis in hepatocytes, although only caspase-8 but not Bid is required for killing of T lymphoid cells (Kang et al., 2004; Kaufmann et al., 2007b; Salmena et al., 2003; Yin et al., 1999).
The roles of caspase-8 and Bid in TNFα-induced apoptosis are still unclear, although Bid deficiency was shown to afford a minor degree of protection in TNFα-treated mouse embryo fibroblasts (MEFs) in vitro and in hepatocytes of mice injected with LPS+GalN (Chen et al., 2007; Zhao et al., 2001). Notably, most studies on TNFα-induced apoptosis have been performed with cells in culture and very little is known about the mechanisms by which overactivation of the immune system causes TNFα-mediated immunopathological tissue destruction. Our experiments with gene-targeted mice demonstrated that TNFα-mediated hepatocyte apoptosis required caspase-8 and involved the proapoptotic BH3-only proteins Bid, activated by caspase-8, and Bim, activated by JNK. These cell-death inducers and effectors can therefore be considered potential therapeutic targets for immunopathological liver disorders.

RESULTS

Caspase-8 Is Essential for LPS+GalN-Induced Hepatocyte Destruction

Experiments with gene-targeted mice demonstrated that expression of caspase-8 within hepatocytes is essential for Fas-antibody-induced hepatocyte killing and fatal hepatitis (Kang et al., 2004). It is, however, not clear whether caspase-8 is also essential for pathological killing of hepatocytes by TNFα. In fact, several studies with cultured cells have indicated that TNFα kills cells by caspase-independent, perhaps even non-apoptotic, mechanisms (reviewed in Ding and Yin, 2004). When mice lacking caspase-8 selectively in hepatocytes (mice homozygous for Casp8 gene flanked by loxP sites expressing a Cre recombinase transgene under control of the hepatocyte-specific albumin [Alb] promoter: Alb-Cre-Casp8fl/fl) were challenged with LPS+GalN, they showed only minor elevation of ALT and AST in serum (Figure 1A; 1998; Luo et al., 1998), injection of WT mice with LPS+GalN caused rapid processing of pro-caspase-8 to produce the active p15 form (tBid), as well as processing and activation of effector caspases, such as caspase-7 (p17) (Figure 1F). No processing of caspase-8, Bid, or effector caspases was seen in liver extracts from LPS+GalN-injected mice lacking TNFα (Figure S4). Collectively, these results demonstrate that upon LPS+GalN injection, activation of caspase-8 within hepatocytes is required for TNFα-mediated liver destruction and fatal hepatitis.

Bid Is a Minor Contributor to LPS+GalN-Induced Hepatocyte Apoptosis

Caspase-8-mediated activation of Bid is essential for Fas-antibody-induced liver destruction (Yin et al., 1999). We confirmed this observation (Kaufmann et al., 2007b) and found that Bid−/− mice are also resistant to FasL (Figure S5). This is an important finding because antibodies to Fas do not always mimic the physiological ligand FasL (Huang et al., 1999).

Although Bid cleavage is readily detectable in the livers of LPS+GalN-treated animals (Figure 1F), recently published data indicate that, in contrast to Fas signaling (Kaufmann et al., 2007a; Yin et al., 1999), TNFα-TNF-R1-induced hepatocyte apoptosis may not be entirely dependent on Bid (Chen et al., 2007). For evaluating the role of Bid in the in vivo killing of hepatocytes by TNFα, WT and Bid−/− mice were challenged with various doses of LPS+GalN. Upon injection of very low doses of LPS (10 ng) plus GalN, Bid−/− mice were clearly less severely affected than WT animals. All WT mice succumbed within 6–8 hr of treatment, whereas all Bid−/− mice remained alive and healthy at that time, presenting with nearly normal ALT and AST serum levels (Figure 2A; Bid−/− versus WT: p < 0.0002 for ALT, p < 0.0001 for AST) and only minor liver destruction (Figure 2C). However, only three out of seven Bid−/− mice survived this treatment for 5 days (experiment stopped thereafter); the other four became terminally ill within 24 hr (Figure 3C). Moreover, when the dose of LPS was increased to 100 or 1000 ng, not only the WT but also all Bid−/− animals succumbed to this treatment within 12 hr, although the serum levels of ALT and AST remained significantly lower in the Bid−/− mice compared to the WT littermates (Figure 2B; p < 0.02 for ALT and p < 0.002 for AST). Consistent with the serum levels of ALT and AST, histological examination of liver sections taken after 6 hr showed extensive hepatocyte destruction in Bid−/− mice (albeit slightly less than in WT controls) after injection of 100 or 1000 ng LPS+GalN (Figure 2C). These results demonstrate that Bid contributes to LPS+GalN-induced hepatocyte apoptosis, but its loss can only delay but not prevent the fatal outcome of this TNFα-mediated process.

Combined Loss of Bid and Bim Potently Protects Mice from LPS+GalN-Induced Fatal Hepatitis

Not only Bid (Li et al., 1998; Luo et al., 1998) but also the related BH3-only protein Bim (encoded by the Bcl2I11 gene, also called Bim) was reported to be activated by caspase-mediated proteolysis (Chen and Zhou, 2004). Therefore, and because Bid plays a major role in apoptosis in many cell types (Bouillet et al., 1999; Huang and Strasser, 2000) and binds avidly to all prosurvival Bcl-2 family members (Chen et al., 2005; Kuwana et al., 2005), we examined whether Bid and Bim cooperate in TNFα-mediated hepatocyte killing in vivo. Interestingly, Bcl2I11−/− mice were less sensitive to injection with 10 ng LPS+GalN (with two of
five mice surviving long-term) than WT animals, although no protection was evident when they were challenged with 100 ng LPS+GalN (Figure 3C). Remarkably, Bcl2l11−/−/Bid−/− mice were more resistant than WT, Bcl2l11−/−, or Bid−/− mice to both 10 and 100 ng LPS+GalN (Figure 3). At the time when all WT, Bid−/−, and Bcl2l11−/− mice were ill, serum ALT and AST levels of Bcl2l11−/−/Bid−/− mice were significantly lower than those found in the control animals (Figure 3A; Bcl2l11−/−/Bid−/− versus WT mice, p < 0.03 for ALT, p < 0.035 for AST). Histological analysis confirmed reduced liver destruction in Bcl2l11−/−/Bid−/− mice compared to all control animals (Figure 3B). Furthermore, eight out of eight Bcl2l11−/−/Bid−/− mice did not get sick when treated with 10 ng LPS+GalN and survived long-term (followed up to 5 days), a dose at which all WT mice succumbed within 6–8 hr and only three out of seven Bid−/− mice and two out of five Bcl2l11−/− mice survived longer than 24 hr (Figure 3C). Remarkably, even at 100 ng LPS+GalN, a dose at which all WT (12/12), all Bid−/− (12/12), and all Bcl2l11−/− (3/3) mice succumbed within 12 hr, five out of seven Bcl2l11−/−/Bid−/− mice survived long-term (followed up to 5 days), even though some went through phases of sickness during the first 24 hr of treatment (Figure 3C and Figure S6). Consistent with the finding that Bid and Bim have overlapping functions in LPS+GalN-induced hepatocyte killing, immunoblotting (Figure S7A) and fluorogenic-enzyme-activity assays (Figure S7B) showed that loss of Bid and to a lesser extent loss of Bim both diminished activation of effector caspases and that loss of both of these BH3-only proteins caused significantly (p < 0.01) greater reduction, particularly at later time points. Synergy between loss of Bid and loss of Bim appears to be specific to LPS+GalN-induced (TNF-mediated) hepatocyte killing because fibroblasts and T lymphocytes from Bcl2l11−/−/Bid−/− mice were either normally...
sensitive or no more resistant than Bcl2l11−/− cells to a diverse range of apoptotic stimuli (Willis et al., 2007 and T.K., P.B., and A.S., unpublished data). These results demonstrate that the two proapoptotic BH3-only proteins Bid and Bim cooperate in TNFα-mediated hepatocyte apoptosis induced by treatment with LPS+GalN.

Mechanisms of Activation of Bid and Bim during LPS+GalN-Induced Hepatitis

Because Bid and Bim play critical overlapping roles in TNFα-induced apoptosis, we investigated how they are activated in hepatocytes from animals injected with LPS+GalN. This treatment caused rapid processing of Bid into the potently proapoptotic truncated tBid form (Figures 1F and 4A). Loss of caspase-8 or pretreatment of WT mice with Q-VD-oph, which affords substantial protection from LPS+GalN-induced hepatitis (Figures 1D and 1E and Figure S3), decreased the production of tBid in LPS+GalN-injected mice and this correlated with a lack of effector-caspase-8 processing and a complete lack of effector-caspase activation (Figure 4A and Figure S2).

Although caspase-mediated activation of BimEL (the most abundantly expressed isoform of Bim in the liver and other tissues [O’Reilly et al., 2000]) has been reported (Chen and Zhou, 2004), we found no evidence for BimEL cleavage in livers of LPS+GalN-injected mice (Figures 4A and 5A). JNK-mediated phosphorylation has also been implicated in the activation of Bim (Lei and Davis, 2003). Notably, a mobility shift in BimEL in liver extracts was observed soon after injection with LPS+GalN (Figures 4A and 5A and Figure S4). Treatment of these extracts with l-phosphatase demonstrated that the modification of Bim was due to a change in phosphorylation (Figure 5B) and examination of livers from LPS+GalN-injected Tnfα−/− mice showed that this change was TNFα dependent (Figure S4). The LPS+GalN-induced phosphorylation of Bim does not require caspase activity, given that the shift in Bim mobility on SDS-PAGE was not affected by prior administration of the pan-caspase inhibitor Q-VD-oph (Figure 4A) or loss of caspase-8 in hepatocytes (Figure 4B).

The proapoptotic activity of Bim can be regulated by its sequestration to microtubules by binding to the dynein motor complex (Puthalakath et al., 1999), and JNK-mediated phosphorylation was reported to cause release and activation of Bim in response to certain stress stimuli (Lei and Davis, 2003; Putcha et al., 2003). We therefore performed subcellular fractionation to examine whether the phosphorylation of Bim seen after LPS+GalN injection affected its sequestration to the microtubular-associated dynein motor complex. Immunoblot analysis of the microtubule-enriched pellet and soluble fractions revealed that the LPS+GalN-treatment-induced phosphorylated form of Bim was released from the microtubular dynein motor complex into the cytosol, whereas the unmodified form of Bim was preferentially detected in the dynein-motor-complex-enriched fraction (Figure 5C). Immunoblotting also revealed an increase of phosphorylated (i.e., activated) JNK in livers of LPS+GalN-injected mice (Figure 5D), and the mobility shift in Bim elicited by...
this treatment was prevented by prior administration of the synthetic JNK-inhibitory D-peptide, D-JNKI1 (Figure 5E). In contrast, D-JNKI1 injection did not affect processing of Bid to tBid (Figure 5E), demonstrating that this inhibitor did not interfere with the LPS+GalN-induced production of TNFα or activation of caspase-8. Importantly, injection of this JNK inhibitor reduced LPS+GalN-induced hepatocyte destruction in Bid−/− mice but not in those lacking Bim (Figures 6A–6C), consistent with the notion that JNK specifically regulates the proapoptotic activity of Bim, which cooperates with Bid in hepatocyte killing. Collectively, these results show that caspase-8-dependent activation of Bid and JNK-induced activation of Bim cooperate in TNFα-mediated hepatocyte destruction in LPS+GalN-injected mice.

**Concanavalin A-Induced Hepatitis Requires Caspase-8 and Involves JNK-Mediated Activation of Bim**

We next tested whether caspase-8 and the BH3-only proteins Bid and Bim are also critical for hepatocyte killing and hepatitis induced in different pathological settings. Injection of concanavalin A (ConA) into mice causes systemic activation of T lymphocytes resulting in fatal hepatitis that is mediated by TNFα (Kusters et al., 1997; Trautwein et al., 1998). When mice lacking caspase-8 selectively in hepatocytes were challenged with ConA, they survived this treatment and showed only minor elevation of serum ALT and AST levels (Figure 7A) and retained normal liver structure (Figure 7B). In contrast, all littermate controls succumbed to this treatment within 6–8 hr, presenting at autopsy with abnormally elevated serum levels of ALT and AST (Figure 7A; caspase-8-deficient versus control mice: p < 0.0035 for both ALT and AST) and extensive disruption of liver architecture (Figure 7B). In contrast to treatment with LPS+GalN, loss of Bid did not confer protection against ConA-induced hepatocyte killing. However, similarly to LPS+GalN injection, we observed rapid increases of phosphorylated (i.e., activated) JNK and phosphorylated Bim in livers of mice challenged with ConA (Figures 7C–7E). This modification in Bim could not be blocked by preadministration of the pan-caspase inhibitor Q-VD-oph (Figure 7F) or specific loss of caspase-8 in hepatocytes (data not shown). Although mice lacking Bim or both Bid and Bim had lower serum levels of ALT and AST compared to ConA-injected WT or Bid−/− mice, these enzymes were still abnormally elevated (Figure 7G). Furthermore, disruption of liver architecture in Bcl2l11−/− and Bcl2l11−/− Bid−/− mice after 6 hr of treatment, although less severe compared to WT or Bid−/− mice (Figure 7H), eventually led to the death of all Bcl2l11−/− as well as Bcl2l11−/− Bid−/− mice. Collectively, these results show that caspase-8 is essential and Bim a contributor in ConA-induced hepatitis, another widely used model of TNFα-mediated liver destruction.

**DISCUSSION**

Overstimulation of the immune system, either by pathogen-associated molecular pattern (PAMP)-mediated activation of cells of the innate immune system or antigenic stimulation of the adaptive arm, plays a major role in immunopathology of the liver as well as
Roles of Caspase-8, Bid, and Bim in Hepatitis

Certain other tissues. This damage is mediated to a large extent through the proapoptotic activity of TNFα (Bradham et al., 1998; Ding and Yin, 2004). The mechanisms by which TNFα kills cells under these conditions remain unclear. Using the widely employed LPS+GalN as well as the ConA injection models of fatal hepatitis, we defined an essential role for caspase-8 and important contributory roles for the two proapoptotic BH3-only Bcl-2 family members Bid and Bim in TNFα-induced tissue destruction. When higher levels of LPS (1000 ng) were administered or with ConA injection, BH3-only proteins were no longer limiting for fatal hepatitis. In contrast, in another model of "death-receptor"-induced fatal hepatitis, mediated by Fas activation, Bid is essential for hepatocyte apoptosis (Kaufmann et al., 2007b; Yin et al., 1999). What could be the reasons for these differences? We speculate that differences in the requirement for Bid, Bim, and possibly additional BH3-only proteins for hepatocyte destruction induced by different death-receptor signals may arise from differences in caspase-8 activity. A higher extent of caspase-8 activity would be expected to cause more direct effector-caspase activation and may also increase apoptosis signaling through direct cleavage of certain vital targets, thereby rendering this pathway to hepatocyte apoptosis less dependent on Bid and other BH3-only proteins (Figure S8). It appears likely that the reduction in the caspase-8 inhibitor c-FLIP (Figure S9A), probably caused by GalN-mediated blockade of its transcriptional inducer NF-κB (Geisler et al., 2007), contributes to the finding that caspase-8 can suffice for LPS+GalN-induced (TNFα-mediated) hepatocyte killing even in the absence of Bid (and Bim). It cannot be excluded that additional differences between TNFα- and FasL-induced hepatocyte killing may arise from the ability of TNF-R1 and TNF-R2 to trigger proapoptotic pathways in addition to caspase-8 activation that are not activated by Fas (Figure S8).

Our genetic studies show that Bim and Bid can both contribute to TNFα-induced apoptosis signaling. The BH3-only proteins Bim and Bid initiate apoptosis signaling through activation of caspase-9 and consequent activation of effector caspases by activating Bax and Bak, either directly and/or indirectly by blocking the prosurvival Bcl-2 family members that keep Bax and Bak in check (Youle and Strasser, 2008). In response to TNFα, Bid is activated by caspase-8-mediated proteolysis (Li et al., 1998; Luo et al., 1998). Although caspase-mediated activation of BimEL has been reported (Chen and Zhou, 2004), we found no evidence for BimEL cleavage in livers of LPS+GalN-injected mice. Caspase-8 might theoretically contribute to Bim activation indirectly, such as by cleaving a protein that controls its sequestration to microtubules, a critical mode of Bim regulation (Puthalakath et al., 1999), but we found no evidence for this (data not shown). Bim does, however, not necessarily have to be activated by caspase-8 to contribute to TNFα-induced apoptosis signaling. Any TNFα-induced signal that activates Bim (see below) would be expected to promote activation of caspase-9 and effector caspases (either on its own or with tBid) because Bim is a potent activator of Bax and Bak (Figure S8 and Youle and Strasser, 2008).

JNK has been implicated in TNFα-induced apoptosis signaling and JNK-mediated phosphorylation has been implicated as a trigger of the proapoptotic activity of Bim by causing its release from sequestration to the microtubular dynein motor complex (Lei and Davis, 2003; Putcha et al., 2003). Remarkably, a mobility shift in BimEL, which was prevented by addition of a highly specific JNK inhibitor, and a redistribution of the posttranslationally modified Bim from microtubules to the cytosol were observed in livers from mice injected with LPS+GalN or ConA. Importantly, injection of the JNK inhibitor reduced LPS+GalN-induced hepatocyte killing in BimEL−/− mice but not in Bcl2/11−/− mice, which...
lack the proapoptotic effector activated by JNK. We therefore conclude that JNK contributes to TNF-R1-induced apoptosis signaling in hepatocytes of LPS+GalN-injected mice by unleashing the proapoptotic activity of Bim. ConA injection causes hepatocytic killing through both secreted and membrane-bound TNFα and therefore involves both TNF-R1 and TNF-R2, whereas LPS+GalN acts mainly through secreted TNFα, which signals only through TNF-R1 (Grivennikov et al., 2005; Nowak et al., 2000; Pfeffer et al., 1993; Rothe et al., 1993). The fact that membrane-bound TNFα can activate JNK through not only TNF-R1 but also TNF-R2 may therefore explain why Bim is more important than Bid in ConA-induced hepatocyte killing (Figure S8).

In contrast to caspase-8 deficiency, combined loss of Bid and Bim did not afford complete protection against LPS+GalN- or ConA-induced hepatic destruction. Some Bcl2l11−/− Bid−/− mice succumbed when injected with higher doses of LPS (e.g., 100 ng) plus GalN, and even some of the long-term survivors went through phases of sickness. Moreover, all Bcl2l11−/− and Bcl2l11−/−/Bid−/− mice injected with ConA became sick and had to be sacrificed, although they exhibited less liver damage than WT or Bid−/− animals. This may indicate that proapoptotic proteins in addition to Bid and Bim (perhaps other BH3-only proteins) contribute to LPS+GalN- and ConA-induced fatal hepatitis. Theoretically, TNFα might also promote apoptosis by causing a reduction in the amounts of prosurvival Bcl-2 family members, but we found no significant changes in Mcl-1 or Bcl-xL (the most highly expressed ones in hepatocytes), in animals treated with LPS+GalN or ConA (Figures S2, S7, and S9B and not shown). As discussed above, we prefer the hypothesis that with increased caspase-8 activation (achieved by increased TNFα-signaling due to increased levels of LPS or injection of ConA), leading to increased direct activation of effector caspases and cleavage of vital proteins, hepatocyte killing may become independent of the BH3-only protein > Bax plus Bak > Apaf-1 > Caspase-9 amplification mechanism for effector-caspase activation (Figure S8). It is noteworthy that it has been speculated that at high doses of LPS, other TNFα-mediated or perhaps even TNFα-independent nonapoptotic death pathways might also be activated in hepatocytes (Kamata et al., 2005). Our experiments with mice lacking caspase-8 in hepatocytes imply, however, that such processes would have to be caspase-8 dependent.
In conclusion, our results show that caspase-8 is essential and the BH3-only proteins Bid and Bim are critical contributors in the pathological killing of hepatocytes that is caused by TNFα in vivo. These observations may have implications for diseases characterized by hepatocellular destruction, indicating that they might respond to treatment with enzymatic inhibitors of caspase-8 or compounds that can antagonize both Bid and Bim.

**EXPERIMENTAL PROCEDURES**

**Mice**
The generation and genotyping of Bid-deficient mice on an inbred C57BL/6 background has been described (Kaufmann et al., 2007b). Bcl2l11-/- mice were originally generated on a mixed C57BL/6x129SV background by homologous recombination in 129SV-derived ES cells but have been backcrossed for more than ten generations onto the C57BL/6 background. The Bcl2l11-/- mice were generated by serially intercrossing the two parental strains. Mice lacking caspase-8 selectively in hepatocytes were generated by crossing mice with a loxP targeted Casp8 gene, generated on a mixed C57BL/6x129SV background and backcrossed with C57BL/6 mice for three generations (Salmena et al., 2003) with transgenic mice expressing the Cre recombinase under control of the hepatocyte-specific albumin promoter (backcrossed onto C57BL/6 background for six generations). TRAIL-deficient (Tnfsf10-/-) mice (Cretney et al., 2002) were generated by homologous recombination in 129SV-derived ES cells and have been backcrossed for more than ten generations onto the C57BL/6 background. TNF-/- mice (generated with C57BL/6 ES cells) (Korner et al., 1997) were obtained from H. Korner, James

---

**Figure 6. Inhibition of JNK Enhances Resistance of Bid-Deficient Mice to LPS+GalN-Induced Hepatocyte Destruction**

(A) Mice of the genotypes indicated were injected with JNK inhibitory peptide D-JNKI1 (30 mg/kg, i.p.) 30 min prior to treatment with 10 ng LPS+GalN and were then monitored for survival for up to 72 hr. Mice injected with LPS+GalN served as controls. We calculated p values with a time-to-event analysis using a log-rank test. (B) Table summarizing the long-term (followed up to 3 days) survival of mice of the indicated genotypes treated with 10 ng LPS+GalN, with or without pretreatment with D-JNKI1. Mice that did not survive all succumbed to the treatment within 24 hr. (C) Serum levels of ALT and AST in Bid-/- mice treated with 10 ng LPS plus 20 mg GalN, with or without pretreatment with D-JNKI1 (30 mg/kg), were measured after 6 hr. p values were as follows: WT versus Bid-/-: p (ALT) = 0.09; p (AST) = 0.16. Each circle represents an individual mouse. Horizontal bars indicate the means of 8–11 mice for each genotype and are derived from three independent experiments.
Cook University, Townsville, Australia. C57BL/6 perforin−/− mice (Kägi et al., 1994) were generated with C57BL/6 ES cells. C57BL/6 GranzymesBM−/− mice were established by intercrossing C57BL/6 GranzymeM−/− mice with C57BL/6 GranzymesAB−/− mice (Pao et al., 2005) (both strains generated with 129Sv ES cells and backcrossed to C57BL/6 for >12 and 8 generations, respectively). All experiments with mice were performed according to the guidelines of the animal ethics committees of the Melbourne Health Research Directorate or the Ontario Cancer Institute.

Figure 7. Caspase-8 Is Essential and Bim a Contributor in ConA-Induced Hepatitis
(A) Mice lacking caspase-8 in hepatocytes (Albumin-Cre transgenic Casp8fl/fl) and littermate controls (Albumin-Cre transgenic Casp8fl/wt mice) were injected with 30 mg/kg ConA. At the time when the control mice were sick (8 hr), all animals were sacrificed and serum levels of ALT and AST were measured. Data shown represent means ± SD of three to five mice for each genotype and each treatment.
(B) H&E-stained histological liver sections from mice treated as in (A). Pictures shown are representative of the analysis of at least three mice for each treatment and genotype.
(C) Liver extracts from WT mice treated with 30 mg/kg ConA for 4 hr were probed by immunoblotting with antibodies specific for phosphorylated (activated) JNK or total JNK (loading control).
(D) WT mice were injected with ConA (30 mg/kg) and sacrificed at the time points indicated. Bim levels and possible posttranslational modifications were analyzed by immunoblotting of liver extracts as described in Figure 5A.
(E) WT mice were injected with 30 mg/kg ConA and sacrificed after 3 hr. Total protein extracts were prepared from the livers of these animals were probed by immunoblotting for Bim.
(F) WT mice, with or without pretreatment with 20 mg/kg of the pan-caspase inhibitor Q-VD-oph, were injected with ConA (30 mg/kg) and sacrificed 5 hr later. Total protein extracts from the livers of these animals were probed by immunoblotting for Bim.
(G) Mice of the genotypes indicated were injected with 30 mg/kg ConA. At the time when the WT mice were sick (6 hr), all animals were sacrificed and serum levels of ALT and AST were measured. Each circle represents measurements from an individual mouse. Horizontal bars indicate the mean.
(H) Histological examination of H&E-stained liver sections of mice of the indicated genotypes subjected for 6 hr to treatment with 30 mg/kg ConA (scale bars represent 50 μm). Pictures shown are representative of the analysis of at least three mice for each genotype.
In Vivo Models of Hepatitis

For Fas-mediated hepatitis, mice were injected intravenously (i.v.) with 0.25 μg/g body-weight recombinant soluble Fas ligand (FLAG-tagged, Apo-tech) that had been crosslinked with 2 μg FLAG antibody (M2, SIGMA) per μg of FasL. For the LPS+GalN model, mice were injected intraperitoneally (i.p.) with 10, 100, or 1000 ng LPS (DIFCO) in the presence of 20 mg of the liver-specific transcriptional inhibitor D-(-)-galactosamine (GalN, SIGMA). For T cell-activation-mediated hepatitis, mice were injected i.v. with 30 mg/kg body weight of ConA (SIGMA). For biochemical studies, at the time when WT mice succumbed to these treatments, all mice of an experimental group were sacrificed and bled (for serum analysis of liver enzymes), and the livers were removed for histological analysis. For survival analysis, mice were treated as indicated and monitored until becoming terminally ill. Statistical analyses were performed by applying a two-tailed unpaired t test. The pan-caspase inhibitor Q-VD-oph (MP Biomedicals) was administered i.p. at 20 mg/kg, 30 min prior to LPS+GalN injection. The D-JNK1 inhibitory peptide (H-Gly-D-Arg-D-Lys-D-Lys-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Pro-D-Pro-D-Pro-D-Arg-D-Pro-D-Lys-D-Arg-D-Pro-D-Thr-D-Thr-D-Thr-D-Leu-D-Asn-D-Leu-D-Phe-D-Pro-D-Gln-D-Val-D-Pro-D-Arg-D-Ser-D-Gln-D-Asp-D-Thr-NH2) (GL Biochem Shanghai Ltd) was administered i.p. at 30 mg/kg, 30 min prior to LPS/GaIN injection.

Immunoblotting and Caspase-Activity Assays

Mouse livers were surgically removed and cell suspensions were prepared by passing them through a stainless-steel sieve. Red blood cells were lysed in a hypotonic buffer and hepatocyte lysates prepared in a buffer containing 20 mM Tris/HCl (pH 7.4), 135 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1% Triton X-100, 10% glycerol, 500 μg/mL Pefabloc (AEBSF), 1 μg/mL Leupeptin, 1 μg/mL Aprotinin, 1 μg/mL Leupeptin, 100 μg/mL soybean trypsin inhibitor, and 2 μg/mL E64. Proteins (40 μg) in cell lysates were size-separated on precast 12% SDS PAGE gradient gels (Invitrogen). Membranes were probed with a rat BID monoclonal antibody (clone 2D1, Alexis; Kauffman et al., 2007b), a polyclonal rabbit BID antibody (Stressgen), a rat anti-mouse caspase-8 monoclonal antibody (clone 1G12, Alexis; O’Reilly et al., 2004), a rabbit polyclonal antibody to active caspase-3 (Cell Signaling), a mouse monoclonal antibody to caspase-7 (gift from Y. Lazebnik), a rabbit monoclonal antibody to c-FLIP (clone Dave-2, Alexis), a rabbit polyclonal antibody to Mcl-1 (Rockland), a mouse monoclonal antibody to phospho-JNK, and a rabbit polyclonal antibody to JNK (both from Cell Signaling). Probing with a mouse monoclonal antibody to i-actin (SIGMA, AC-40) served as a loading control.

A fluorogenic assay for effector caspase activity in liver extracts was performed according to the manufacturer’s (Bachem, Switzerland) protocols.

Subcellular Fractionation

Subcellular fractionation was performed as described earlier (Ruthalakath et al., 1999). In brief, ~5 × 109 liver cells from mice injected with PBS, GaIN, or LPS+GalN were lysed in 500 μl of extraction buffer (0.05 M PIPES-NaOH, 0.05 M HEPES [pH 7.0], 2 mM MgCl2, 1 mM EDTA, 1 mM DTT plus protease, and phosphatase inhibitors) containing 1% Triton X-100. Cell debris and nuclei were removed by centrifugation at 500,000 g for 30 min at 37°C. The supernatant was spun at 125,000 × g for 60 min at 4°C and the filamentous actin-enriched pellet (P1) was discarded. The remaining supernatant was incubated for 13 min at 37°C with 20 μL taxol and 5 U apyrase (Sigma). This mixture was gently laid on top of 0.5 ml sucrose and 5 U apyrase (Sigma). This mixture was gently laid on top of 0.5 ml sucrose containing 7.5% sucrose and centrifuged at 500,000 g for 30 min at 125,000 × g at 30°C. The sedimented pellet was saved as the dynein-enriched P2 fraction and the supernatant as the S fraction.

SUPPLEMENTAL DATA

Supplemental Data include nine figures and can be found with this article online at http://www.immunity.com/supplemental/S1074-7613(08)00543-8.

ACKNOWLEDGMENTS

We are grateful to J. Adams, S. Cory, D. Huang, K. Rajewski, H. Koerner, and Y. Lazebnik for gifts of gene-targeted mice or antibodies. We thank K. Vella, N. Iannarella, and G. Siciliano for animal care, C. Young and D. Chau for excellent technical assistance, M. Robati and B. Helbert for genotyping, the Biochemistry Department of the Royal Melbourne Hospital for ALT and AST measurements, and J. Adams, S. Cory, D. Huang, D. Vaux, and L. O’Reilly for advice and critical comments on the manuscript. This work was supported by grants (program #257502) and fellowships from the NHMRC (Canberra, the NCI (NIH, USA; #CA 80188 and #CA 43540), the Leukemia and Lymphoma Society of America (SCOR grant #7015), the JDRF/NHMRC, the Swiss National Science Foundation, the Roche Research Foundation, the Novartis Foundation (formerly Ciba-Geigy-Jubilaeumsstiftung; postdoctoral fellowships to T.K.) and the Mildred-Scheel Stiftung/Deutsche Krebshilfe (postdoctoral fellowship to P.U.J.). V.M.D. is an employee at Genentech, Inc.

Received: June 10, 2008
Revised: September 26, 2008
Accepted: October 20, 2008
Published online: December 31, 2008

REFERENCES


